Despite growing awareness, significant barriers continue to slow progress in closing the women’s health gap. Biased datasets, chronic underinvestment in female-focused research, and insufficient policy frameworks continue to limit our understanding of women’s health outcomes and their broader impact on healthcare delivery and economies.

At the same time, guidance from leading regulators such as the U.S. FDA is clear: clinical trials must prioritize sex-balanced enrollment, researchers must conduct sex-specific data analyses and study populations must better reflect real-world diversity.

Join Cytel’s experts for a panel discussion exploring how closing the women’s health gap requires a structural transformation across biostatistics and data management, from redesigning studies, applying sex-sensitive statistical methodologies, data governance to generate more inclusive evidence, and supporting the development of therapies that work better for all patients.

Key Topics

• The current challenges contributing to the women’s health gap
• Why sex-specific analyses are becoming increasingly important in clinical development
• Improving study design to better capture sex and gender differences
• The role of biostatistics and data governance in generating inclusive evidence
• Aligning women-focused research strategies with evolving regulatory expectations

Panelists

Michelle Hoiseth, Senior Vice President, Project Based Services

Nelia Padilla, Vice President, Consulting Strategy & Operations

Grammati Sarri, Vice President, Innovative Statistics, Evidence, Value, Access & Health Policy